₹5081.95 305.9 6.4%
Last Trade - 13/04/21
| Market Cap | £2.26bn |
| Enterprise Value | £2.17bn |
| Revenue | £214.1m |
| Position in Universe | 167th / 3106 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Mar | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 18,533 | 20,938 | 20,419 | 19,802 | 20,815 | 21,517 | 22,541 | 24,435 | +3.0% | ||
| -60.2 | +122.6 | -15.9 | +43.3 | +13.9 | +18.4 | +6.68 | +7.47 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Pfizer Limited is an India-based pharmaceutical company. The Company has a portfolio of approximately 140 products across over 15 therapeutic areas. The Company is engaged in manufacturing, marketing, trading and exporting pharmaceutical products. The Company offers a range of products for Anti-Allergic, Anti-Diabetic, Antihistamine, Anti-Infectives, Cardiovascular, Dermatology, Erectile Dysfunction, gastrointestinal (GI), Multivitamins, Pain/Inflammation+GI, Respiratory, Urology and Vitamin/Minerals, among others. Its products include LC-OD Plus, Bidiab, Voglibose, Histizer, Isokin, Jetex Suspension, Nebasulf Ointment, Trulimax, Combantrin A, Newsta, Selsun, Agarol, Oxileptin, Ponstan, Daxid, Tricorex, Citrosoda and Cognisules, among others. The Company has its own manufacturing facility at Thane and Goa. The Company has various independent contract/third party manufacturers based across the country. The Company sells its products through independent distributors primarily in India.
| Last Annual | March 31st, 2020 |
| Last Interim | December 31st, 2020 |
| Incorporated | November 21, 1950 |
| Public Since | December 9, 1994 |
| No. of Shareholders: | 85,972 |
| No. of Employees: | 2,489 |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | |
| Exchange | National Stock Exchange of India |
| Shares in Issue | 45,750,000 |
| Free Float | (0.0%) |
| Eligible for |
✓
ISAs
✓
SIPPs
|
| Address | Pfizer Centre 5 Patel Estate,Off SV Road Jogeshwari (W), MUMBAI, 400051, India |
| Web | http://www.pfizerindia.com/ |
| Phone | +91 22 66932000 |
| Contact | Nutan Shirke (IR Contact Officer) |
| Auditors | Walker Chandiok & Co LLP |
As of 13/04/21, shares in Pfizer are trading at ₹5081.95, giving the company a market capitalisation of £2.26bn. This share price information is delayed by 15 minutes.
Shares in Pfizer are currently trading at ₹5081.95 and the price has moved by 22.1% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Pfizer price has moved by -23.21% over the past year.
Of the analysts with advisory recommendations for Pfizer, there are there are currently 3 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Pfizer is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Pfizer is scheduled to issue upcoming financial results on the following dates:
The Pfizer dividend yield is 0.2% based on the trailing twelve month period.
Last year, Pfizer paid a total dividend of 10, and it currently has a trailing dividend yield of 0.2%. Looking ahead, Pfizer has not announced an ex-dividend date yet.
Pfizer has yet to annouce their ex-dividend date. The historic dividend yield on Pfizer shares is currently 0.2%.
To buy shares in Pfizer you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Pfizer are currently trading at ₹5081.95, giving the company a market capitalisation of £2.26bn.
Here are the trading details for Pfizer:
Based on an overall assessment of its quality, value and momentum, Pfizer is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Pfizer are currently priced at ₹5081.95. At that level they are trading at 4.46% discount to the analyst consensus target price of 0.00.
Analysts covering Pfizer currently have a consensus Earnings Per Share (EPS) forecast of 113.225 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pfizer. Over the past six months, the relative strength of its shares against the market has been -17.19%. At the current price of ₹5081.95, shares in Pfizer are trading at 6.69% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pfizer PE ratio based on its reported earnings over the past 12 months is 46.94. The shares are currently trading at ₹5081.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pfizer's management team is headed by:
Here are the top five shareholders of Pfizer based on the size of their shareholding:
